EyePoint Pharmaceuticals, Inc. (EYPT) Stock

EyePoint Pharmaceuticals, Inc. (EYPT) is a Technology stock trading at $13.59 (as of 2026-06-18), with a market capitalization of $1.14B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

EyePoint Pharmaceuticals, Inc. develops and commercializes ophthalmic therapies for eye diseases. Its products include ILUVIEN, YUTIQ, and DEXYCU, and it is also developing EYP-1901 and YUTIQ50; the company operates in the United States, China, and the United Kingdom.

Valuation — source: SEC EDGAR (first-party)
Price$13.59
Market Cap$1.14B
Price / Sales1635.87
DCF Value (model)$-48.44
DCF Upside vs Price-456.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$31.37M
Net Margin-739.4%
Revenue Growth (YoY)-97.2%
EPS Growth (YoY)52.3%
FCF Growth (YoY)52.7%
Financial Health — source: SEC EDGAR
Altman Z-Score6.34 (safe)
Valuation vs Sector & Industry
Sector P/E (Technology)32.6
Industry P/E (Measuring & Control Equipment)60.1
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSUVRETTA CAPITAL MANAGEMENT, LLC ($106.94M)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEOJay S. Duker
Employees165
CountryUS
IPO Date2005-01-27

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • PROCEPT BioRobotics Corporation (PRCT)
  • Cadre Holdings, Inc. (CDRE)
  • AxoGen, Inc. (AXGN)
  • Enovis Corporation (ENOV)
  • NovoCure Limited (NVCR)
  • Beta Bionics, Inc. (BBNX)
  • CONMED Corporation (CNMD)
  • IRadimed Corporation (IRMD)
EYPT earnings history · EYPT institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.